Ebola Virus Disease, Vaccines, Therapeutics, Transmission, and Long-Term Sequelae: Scoping Review with ☸️SAIMSARA

Name: SAIMSARA Evidence Object infections::EBOLA_PM
Creator: SAIMSARA
License: https://saimsara.com/license/

SAIMSARA

doi:10.62487/saimsara976931fc

SAIMSARA Journal

Machine-Readable Science • ISSN 3054-3991

Ebola Virus Disease, Vaccines, Therapeutics, Transmission, and Long-Term Sequelae: Scoping Review with ☸️SAIMSARA

Infectious Diseases

Issue 7, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsara976931fc

Editorial note

• Last update: 2026-06-06 23:48:06

What is this paper about

Built on 810 linked references, this review maps the evidence on Ebola virus disease — from vaccines and monoclonal antibodies to relapse, viral persistence, survivor sequelae, diagnostics, outbreak control, and hidden system failures — making the full read valuable for anyone who wants the whole Ebola evidence landscape in one place.

Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.

Generated with SAIMSARA v5.2

Video summary generated from this ☸️SAIMSARA evidence map. Full reference-linked paper and evidence JSON are available after purchase.

Abstract: To map and synthesize the original research evidence on Ebola virus disease, including clinical presentation and prognosis, transmission and outbreak control, diagnostics, vaccines, therapeutics, pathophysiology, survivor sequelae, health-system effects, and implementation challenges. The review uses 810 references and builds its evidence map from 2251 original studies with 4785212 total participants/sample observations (topic-deduplicated ΣN). This scoping review indicates that Ebola virus disease outcomes are consistently shaped by viral load, age, organ dysfunction, and the timeliness of effective care, with case fatality reaching 62.9% across the 2013–2016 West African epidemic and exceeding 80% in children under five years and older adults. The evidence supports a role for rVSV-ZEBOV vaccination in reducing both infection risk and mortality among confirmed cases, while monoclonal antibody therapies MAb114 and REGN-EB3 were associated with substantially lower mortality than ZMapp in a randomized trial. Transmission control depends on rapid diagnosis, contact tracing, safe burial, and community trust, yet persistent viral reservoirs in immune-privileged sites and documented relapse events underscore the need for sustained survivor monitoring. The mapped literature highlights that health-system resilience, infection prevention infrastructure, and community engagement are critical modifiers of outbreak trajectory, though evidence from non-outbreak and high-resource settings remains limited. Future research should prioritize standardized longitudinal cohort designs with extended follow-up to resolve uncertainties around long-term sequelae, viral persistence, and the durability of vaccine- and treatment-induced protection.

Keywords: Ebola virus disease; Ebola virus; EBOV transmission; Ebola outbreaks; case fatality; EVD survivors; long-term sequelae; rVSV-ZEBOV vaccine; Ebola treatment units; viral persistence

Review Stats

Final search date and database lock: 2026-06-06 18:51:25 CEST
Plan: Pro (expanded craft tokens; source: PubMed)
Source: PubMed
Total Abstracts/Papers: 4585
Downloaded Abstracts/Papers: 4585
Included original and non-original Abstracts/Papers (all): 4089
Included original Abstracts/Papers (Vote counting by direction of effect): 2251
Reference Index (links used in paper): 810
Total participants/sample observations (topic deduplicated ΣN): 4785212

Get access to the full paper

Unlock the full evidence map

Full paper access includes the complete human-readable review, figures, reference index, PDF export, and machine-readable Evidence JSON download.
Evidence JSON can also be purchased separately if you only need the LLM-ready object for agent, AI, or RAG workflows.
Institutional or library access? Sign in with your institution email to open all available SAIMSARA papers under your institution access arrangement.
Need a SAIMSARA review on your own topic? ☸️Request.

Reference Index (810)

[1] Ebola Virus Disease: Epidemiology, Clinical Features, Management, and Prevention. — https://doi.org/10.1016/j.idc.2019.08.005
[2] Ebola Virus: Pathogenesis and Countermeasure Development. — https://doi.org/10.1146/annurev-virology-092818-015708
[3] Therapeutic Strategies against Ebola Virus Infection. — https://doi.org/10.3390/v14030579
[4] Ebola Virus Disease and Current Therapeutic Strategies: A Review. — https://doi.org/10.1007/978-3-030-78787-5_18
[5] Ebola virus disease mathematical models and epidemiological parameters: a systematic review. — https://doi.org/10.1016/s1473-3099(24)00374-8
[6] Ebola virus disease: An emerging and re-emerging viral threat. — https://doi.org/10.1016/j.jaut.2019.102375
[7] Ebola haemorrhagic fever. — https://doi.org/10.1016/s0140-6736(10)60667-8
[8] Care of the child with Ebola virus disease. — https://doi.org/10.1097/pcc.0000000000000358

Unlock the full paper to view the complete Reference Index.